An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain
Open-Label Extension, Single-Arm, Flexible-Dosing, Phase 3 Trial With CG5503 Extended-Release (ER) in Patients With Moderate to Severe Chronic Pain
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Adelaide, Australia
-
Melbourne, Australia
-
Newcastle, Australia
-
Woodville North, Australia
-
-
-
-
-
Halifax, Canada
-
-
British Columbia
-
Chilliwack, British Columbia, Canada
-
Kelowna, British Columbia, Canada
-
Penticton, British Columbia, Canada
-
Vancouver, British Columbia, Canada
-
-
Newfoundland and Labrador
-
St. John'S, Newfoundland and Labrador, Canada
-
-
Ontario
-
Ajax, Ontario, Canada
-
Brampton, Ontario, Canada
-
Kitchener, Ontario, Canada
-
London, Ontario, Canada
-
Markham, Ontario, Canada
-
Mississauga, Ontario, Canada
-
Ottawa, Ontario, Canada
-
Sarnia, Ontario, Canada
-
Sudbury, Ontario, Canada
-
Toronto, Ontario, Canada
-
Vancouver, Ontario, Canada
-
-
Prince Edward Island
-
Charlottetown, Prince Edward Island, Canada
-
-
Quebec
-
Montreal, Quebec, Canada
-
Pointe-Claire, Quebec, Canada
-
Sherbrooke, Quebec, Canada
-
St. Romuald, Quebec, Canada
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canada
-
-
-
-
-
Christchurch, New Zealand
-
Tauranga, New Zealand
-
Wellington, New Zealand
-
-
-
-
Alabama
-
Birmingham, Alabama, United States
-
Hoover, Alabama, United States
-
Mobile, Alabama, United States
-
-
Arizona
-
Mesa, Arizona, United States
-
Phoenix, Arizona, United States
-
Tempe, Arizona, United States
-
Tucson, Arizona, United States
-
-
Arkansas
-
Jonesboro, Arkansas, United States
-
Little Rock, Arkansas, United States
-
-
California
-
Anaheim, California, United States
-
Carmichael, California, United States
-
Encinitas, California, United States
-
Fresno, California, United States
-
Huntington Park, California, United States
-
Laguna Hills, California, United States
-
Los Gatos, California, United States
-
Pico Rivera, California, United States
-
Pismo Beach, California, United States
-
Sacramento, California, United States
-
San Diego, California, United States
-
Upland, California, United States
-
Westlake Village, California, United States
-
-
Connecticut
-
Stamford, Connecticut, United States
-
Trumbull, Connecticut, United States
-
-
Florida
-
Chiefland, Florida, United States
-
Clearwater, Florida, United States
-
Fort Myers, Florida, United States
-
Hallandale Beach, Florida, United States
-
Hollywood, Florida, United States
-
Jacksonville, Florida, United States
-
Kissimmee, Florida, United States
-
Miami, Florida, United States
-
New Port Richey, Florida, United States
-
Oldsmar, Florida, United States
-
Pembroke Pines, Florida, United States
-
Plantation, Florida, United States
-
Port Orange, Florida, United States
-
Sarasota, Florida, United States
-
Tamarac, Florida, United States
-
Tampa, Florida, United States
-
-
Georgia
-
Athens, Georgia, United States
-
Augusta, Georgia, United States
-
Decatur, Georgia, United States
-
Marietta, Georgia, United States
-
Perry, Georgia, United States
-
Suwanee, Georgia, United States
-
Woodstock, Georgia, United States
-
-
Hawaii
-
Honolulu, Hawaii, United States
-
-
Idaho
-
Boise, Idaho, United States
-
Meridian, Idaho, United States
-
-
Illinois
-
Chicago, Illinois, United States
-
-
Indiana
-
Avon, Indiana, United States
-
Evansville, Indiana, United States
-
Indianapolis, Indiana, United States
-
Valparaiso, Indiana, United States
-
-
Iowa
-
West Des Moines, Iowa, United States
-
-
Kansas
-
Overland Park, Kansas, United States
-
Prairie Village, Kansas, United States
-
Topeka, Kansas, United States
-
-
Kentucky
-
Madisonville, Kentucky, United States
-
-
Louisiana
-
Baton Rouge, Louisiana, United States
-
Lake Charles, Louisiana, United States
-
Mandeville, Louisiana, United States
-
Metairie, Louisiana, United States
-
New Orleans, Louisiana, United States
-
-
Maryland
-
Columbia, Maryland, United States
-
Owings Mills, Maryland, United States
-
Rockville, Maryland, United States
-
-
Massachusetts
-
Boston, Massachusetts, United States
-
Brighton, Massachusetts, United States
-
Fall River, Massachusetts, United States
-
N Dartmouth, Massachusetts, United States
-
W Yarmouth, Massachusetts, United States
-
Wellesley Hills, Massachusetts, United States
-
-
Michigan
-
East Lansing, Michigan, United States
-
Grand Blanc, Michigan, United States
-
Kalamazoo, Michigan, United States
-
Troy, Michigan, United States
-
-
Missouri
-
Saint Louis, Missouri, United States
-
-
Nebraska
-
Omaha, Nebraska, United States
-
-
New Jersey
-
Cherry Hill, New Jersey, United States
-
-
New Mexico
-
Albuquerque, New Mexico, United States
-
-
New York
-
Mamaroneck, New York, United States
-
New York, New York, United States
-
Williamsville, New York, United States
-
-
North Carolina
-
Greensboro, North Carolina, United States
-
Raleigh, North Carolina, United States
-
Winston Salem, North Carolina, United States
-
-
Ohio
-
Cincinnati, Ohio, United States
-
Kettering, Ohio, United States
-
Toledo, Ohio, United States
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States
-
-
Oregon
-
Medford, Oregon, United States
-
-
Pennsylvania
-
Allentown, Pennsylvania, United States
-
Chester, Pennsylvania, United States
-
Duncansville, Pennsylvania, United States
-
Morrisville, Pennsylvania, United States
-
Philadelphia, Pennsylvania, United States
-
-
South Carolina
-
Greenville, South Carolina, United States
-
Prosperity, South Carolina, United States
-
-
South Dakota
-
Sioux Falls, South Dakota, United States
-
-
Tennessee
-
Clarksville, Tennessee, United States
-
Nashville, Tennessee, United States
-
-
Texas
-
Amarillo, Texas, United States
-
Austin, Texas, United States
-
Dallas, Texas, United States
-
Houston, Texas, United States
-
Hurst, Texas, United States
-
Lubbock, Texas, United States
-
Odessa, Texas, United States
-
San Antonio, Texas, United States
-
-
Utah
-
Salt Lake City, Utah, United States
-
-
Virginia
-
Danville, Virginia, United States
-
Roanoke, Virginia, United States
-
Virginia Beach, Virginia, United States
-
-
Washington
-
Bellevue, Washington, United States
-
Tacoma, Washington, United States
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Non-lactating female subjects (Sexually active women must be postmenopausal, surgically sterile, or practicing an effective method of birth control [e.g., prescription oral contraceptives, contraceptive injections, intrauterine device, double barrier method, contraceptive patch, male partner sterilization] before entry and throughout the trial. Female patients of childbearing potential must have a negative pregnancy test at screening.)
- Completion of the expected double-blind treatment period of the pivotal Tapentadol (CG5503) Phase 3 trials in osteoarthritis (R331333-PAI-3008, KF5503/11) or low back pain (R331333-PAI-3011, KF5503/23), or completion of the 1-year treatment period of the safety CG5503 Phase 3 trial in the non-European sites (R331333-PAI-3007, KF5503/24)
- Must be willing to take Tapentadol (CG5503) extended release (ER) and the rescue medication supplied for the duration of the trial
Exclusion Criteria:
- History of alcohol and/or drug abuse, life-long history of seizure disorder or epilepsy, any of the following within the past year: mild/moderate traumatic brain injury, stroke, transient ischemic attack, or brain neoplasm
- Severe traumatic brain injury within the past 15 years
- Uncontrolled hypertension (repeated systolic blood pressure >160 mmHg or diastolic blood pressure >95 mmHg)
- Severely impaired renal function
- Moderately or severely impaired hepatic function
- Patients taking neuroleptics, monoamine oxidase inhibitors, or tricyclic antidepressants within 14 days prior to screening.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 001
Tapentadol (CG5503) Extended Release (ER) 100 150 200 250 mg oral tablet twice daily for 52 weeks
|
100, 150, 200, 250 mg oral tablet twice daily for 52 weeks
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Subjects With Treatment-emergent Adverse Events (TEAE)
Time Frame: 52 weeks
|
The number of subjects who reported a TEAE during the treatment period.
TEAE was defined as any adverse event that started or worsened on or after the start of the study medication and up to 3 days after the discontinuation of the study medication.
|
52 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From Baseline in Average Pain Intensity Scores at Week 52 Using the Numerical Rating Scale (NRS)
Time Frame: Baseline, 52 weeks
|
The subjects indicated the average level of pain experienced, at each study visit, over the previous 24 hours on an 11-point Numerical Rating Scale (NRS) where a score of 0 indicated "no pain" and a score of 10 indicated "pain as bad as you can imagine".
|
Baseline, 52 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pain
- Neurologic Manifestations
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Arthritis
- Osteoarthritis
- Back Pain
- Low Back Pain
- Chronic Pain
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Opioid
- Narcotics
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Adrenergic Uptake Inhibitors
- Tapentadol
Other Study ID Numbers
Other Study ID Numbers
- CR013567
- R331333PAI3010
- KF18
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.